Lack of Efficacy of an Inhibitor of PDE4 in Phase 1 and 2 Trials ofPatients With Nonalcoholic Steatohepatitis

Clinical Gastroenterology and Hepatology

Volumn 12, Issue 10, 2014, Pages 1724-1730.e5

[No Author Info available]

Author keywords

Fatty Liver Disease; PDE4; Therapeutic Targets; Treatment

Indexed keywords

ADIPONECTIN; ALANINE AMINOTRANSFERASE; ANTIFIBROTIC AGENT; ANTIINFLAMMATORY AGENT; ASP 9831; ASPARTATE AMINOTRANSFERASE; CYTOKERATIN 18; PHOSPHODIESTERASE IV INHIBITOR; PLACEBO; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; AREA UNDER THE CURVE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CONNECTIVE TISSUE DISEASE; CONTROLLED STUDY; DIZZINESS; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG ELIMINATION; DRUG ERUPTION; DRUG FATALITY; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG WITHDRAWAL; DYSPEPSIA; EAR DISEASE; ELIMINATION HALF-LIFE; FEMALE; GASTROINTESTINAL DISEASE; HUMAN; IMMUNOPATHOLOGY; INFECTION; INFESTATION; INNER EAR DISEASE; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MEDIASTINUM DISEASE; MENTAL DISEASE; MUSCLE SPASM; MUSCULOSKELETAL DISEASE; NEUROLOGIC DISEASE; NONALCOHOLIC FATTY LIVER; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT DISEASE; SINGLE DRUG DOSE; THORAX DISEASE; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT DURATION; TREATMENT OUTCOME; URINARY TRACT DISEASE; ADOLESCENT; AGED; BLOOD; CLINICAL TRIAL; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; PATHOLOGY; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ALANINE TRANSAMINASE; ASPARTATE AMINOTRANSFERASES; FEMALE; HUMANS; MALE; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; PHOSPHODIESTERASE 4 INHIBITORS; PLACEBOS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84908090042     PISSN: 15423565     EISSN: 15427714     Source Type: Journal    
DOI: 10.1016/j.cgh.2014.01.040     Document Type: Article

References (19)

1. Chalasani N., Younossi Z., Lavine J.E., et al. The diagnosis and management of non-alcoholic fatty liver disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology 2012, 55:2005-2023.
2. Ratziu V., Bellentani S., Cortez-Pinto H., et al. Aposition paper on NAFLD/NASH based on the EASL 2009 Special Conference. JHepatol 2010, 53:372-384.
3. Sanyal A.J., Chalasani N., Kowdley K.V., et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. NEngl J Med 2010, 362:1675-1685.
4. Neuschwander-Tetri B.A. Hepatic lipotoxicity and the pathogenesis of nonalcoholic steatohepatitis: the central role of nontriglyceride fatty acid metabolites. Hepatology 2010, 52:774-788.
5. Cusi K. Role of obesity and lipotoxicity in the development of nonalcoholic steatohepatitis: pathophysiology and clinical implications. Gastroenterology 2012, 142:711-725.
6. Dastidar S.G., Rajagopal D., Ray A. Therapeutic benefit of PDE4 inhibitors in inflammatory diseases. Curr Opin Investig Drugs 2007, 8:364-372.
7. Lugnier C. Cyclic nucleotide phosphodiesterase (PDE) superfamily: a new target for the development of specific therapeutic agents. Pharmacol Ther 2006, 109:366-398.
8. Spina D. PDE4 inhibitors: current status. Br J Pharmacol 2008, 155:308-315.
9. Lebrec D., Thabut D., Oberti F., et al. Pentoxifylline does not decrease short-term mortality but does reduce complications in patients with advanced cirrhosis. Gastroenterology 2010, 138:1755-1762.
10. Sanyal A.J., Brunt E.M., Kleiner D.E., et al. Endpoints and clinical trial design for nonalcoholic steatohepatitis. Hepatology 2011, 54:344-353.
11. Belfort R., Harrison S.A., Brown K., et al. Aplacebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. NEngl J Med 2006, 355:2297-2307.
12. Ratziu V., Sheikh M.Y., Sanyal A.J., et al. Aphase 2, randomized, double-blind, placebo-controlled study of GS-9450 in subjects with nonalcoholic steatohepatitis. Hepatology 2012, 55:419-428.
13. Ratziu V., de Ledinghen V., Oberti F., et al. Arandomized controlled trial of high-dose ursodeoxycholic acid for nonalcoholic steatohepatitis. JHepatol 2011, 54:1011-1019.
14. Ratziu V., Giral P., Jacqueminet S., et al. Rosiglitazone for nonalcoholic steatohepatitis: one-year results of the randomized placebo-controlled Fatty Liver Improvement with Rosiglitazone Therapy (FLIRT) trial. Gastroenterology 2008, 135:100-110.
15. Zein C.O., Yerian L.M., Gogate P., et al. Pentoxifylline improves nonalcoholic steatohepatitis: a randomized placebo-controlled trial. Hepatology 2011, 54:1610-1619.
16. Timmer W., Leclerc V., Birraux G., et al. The new phosphodiesterase 4 inhibitor roflumilast is efficacious in exercise-induced asthma and leads to suppression of LPS-stimulated TNF-alpha exvivo. JClin Pharmacol 2002, 42:297-303.
17. Lin H.Z., Yang S.Q., Chuckaree C., et al. Metformin reverses fatty liver disease in obese, leptin-deficient mice. Nat Med 2000, 6:998-1003.
18. Musso G., Gambino R., Cassader M., et al. Ameta-analysis of randomized trials for the treatment of nonalcoholic fatty liver disease. Hepatology 2010, 52:79-104.
19. Galli A., Crabb D.W., Ceni E., et al. Antidiabetic thiazolidinediones inhibit collagen synthesis and hepatic stellate cell activation invivo and invitro. Gastroenterology 2002, 122:1924-1940.